Bitcoin price today: slips below $113k, near 6-wk low despite Fed cut bets
Houston-based biopharmaceutical company Marker Therapeutics, Inc., with a market capitalization of $20.45 million, reported a change in its board composition earlier this week. On Thursday, the firm announced the resignation of Mr. John Wilson from its Board of Directors, effective January 24, 2025. The details surrounding Mr. Wilson’s departure have not been disclosed, and the company has not named a successor at this time.
Marker Therapeutics, operating under the trading symbol (NASDAQ:MRKR), is known for its specialization in pharmaceutical preparations. Despite recent stock performance challenges, including a 38% decline year-to-date, the company has shown strong revenue growth of 79% in the last twelve months. The company’s corporate headquarters is located at 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251, Houston, Texas, 77021. Marker Therapeutics, previously known as TapImmune Inc., has undergone several name changes in its history, the last of which occurred on June 29, 2017.
The company’s announcement came through a Form 8-K filing with the Securities and Exchange Commission (SEC), which is a requirement for publicly traded companies to report significant events that shareholders should know about. The 8-K form is a standard means for Marker Therapeutics and other companies to communicate changes in their corporate governance and financial status.
The resignation of a board member is an event of interest to investors and stakeholders as it may signal changes in the company’s strategic direction or governance. However, the company has not provided further details on the circumstances leading to Mr. Wilson’s resignation or its plans to fill the vacancy.
Marker Therapeutics’ stock is listed on The Nasdaq Stock Market LLC, where it trades under the symbol MRKR. As of the last report, there has been no immediate market reaction to the announcement of Mr. Wilson’s departure from the board. According to InvestingPro, the company maintains a healthy financial position with a current ratio of 3.15, indicating strong liquidity to meet short-term obligations. InvestingPro analysis suggests the stock may be undervalued at its current price of $1.92.
This news is based on the latest SEC filing by Marker Therapeutics and does not include any speculative content or additional commentary. The company’s contact number is (713) 400-6400 for those seeking further information. For deeper insights into Marker Therapeutics’ financial health and additional analysis, investors can access more than 10 exclusive ProTips and comprehensive financial metrics through InvestingPro.
In other recent news, Marker Therapeutics reported promising results from their lymphoma study, with a 78% objective response rate and 44.4% achieving complete response at the first assessment. The company has also seen a significant revenue growth of 79% in the last twelve months. However, analysts do not anticipate the company reaching profitability this year. In addition, Marker Therapeutics received a substantial $9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) for a clinical study of their immunotherapy product, MT-601, for metastatic pancreatic cancer patients. This funding, along with a $2 million award from the NIH Small Business Innovation Research (SBIR) program, is expected to propel MT-601’s clinical program, set to begin in 2025. The company continues to focus on operational excellence and the advancement of its T cell-based immunotherapies to improve patient outcomes. These are among the recent developments at Marker Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.